Lytix Biopharma AS at its ordinary general meeting held on 18 April 2023, elected Marie Ann Roskrow (chairperson); In accordance with the nomination committee's recommendation and the board's proposal, the general meeting elected that the current nomination committee members will remain for the period until the Company's ordinary general meeting in 2024. The committee consists of: Per Erik Sørensen (Chairperson); Lise von Tangen Jordan; Steinar Thoresen. Dr Roskrow holds a medical degree and a PhD in Immunology and serves currently as the Chairman of a number of international biotechnology companies.

In addition to high level clinical and research positions, Dr. Roskrow has extensive experience as an investment banker, CEO and Chairman in both private and listed companies, such as the GSF Research Institute (Munich), Patrys Ltd. (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). She has also participated in dozens of public and private biotechnology and pharmaceutical merger and acquisition deals, company financings and product in/out-licensing deals.